CDK4 and breast carcinoma: The selective CDK4/6 inhibitors (CDK4/6is)–palbociclib, ribociclib, and abemaciclib– are potent agents that arrest cell-cycle progression and demonstrate clinical efficacy in HR+ breast cancer, particularly when combined with anti-estrogen therapy [8].